Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Pipeline Monitor
Takeda files Velcade successor
Takeda's filing of oral multiple myeloma treatment ixazomib has been accepted in Europe while Novartis has won US extension of Promacta.
Open Forum
Australia must agree on biosimilar approach
With the PBAC opinion on Remicade biosimilar Inflectra due today, Dr Greg Pearce writes it is in everyone's best interest to think beyond sectional interests and foster a sound approach to biosimilar medicine market entry.